文献速递胸部肿瘤放疗

风险适应性立体定向放疗治疗大(>3 cm)原发性肺癌伴或不伴组织学确诊:倾向评分匹配与加权分析

Risk-adapted stereotactic body radiation therapy for the treatment of large (>3 cm) primary lung cancer with or without histologic confirmation: A propensity score matched and weighted analysis.
PubMed 文献 · Radiother Oncol · 2025-02-09

研究纳入2010年11月1日至2022年12月31日期间126例大(>3 cm)原发性肺癌患者,接受风险适应性立体定向放疗(中位5次,总剂量60 Gy,范围45-63 Gy),其中临床诊断61例(48.4%)、病理诊断65例(51.6%)。经倾向评分匹配与逆概率治疗加权后,临床诊断与病理诊断患者在总生存、无进展生存、肿瘤失败及癌症特异性死亡方面未见差异。作者结论认为风险适应性立体定向放疗可能是经过适当选择的、缺乏组织学确诊的大(>3 cm)原发性肺癌患者的优选治疗。

要点

  • 大(>3 cm)原发性肺癌接受风险适应性立体定向放疗,中位5次、总剂量60 Gy(范围45-63 Gy)。
  • 倾向评分匹配与加权后,临床诊断与病理诊断患者的总生存、无进展生存、肿瘤失败及癌症特异性死亡未见差异。
  • 病理诊断组1例(0.8%)在立体定向放疗后2个月发生5级肺炎。

核心结论

  • 风险适应性立体定向放疗可能是经过适当选择的、缺乏组织学确诊的大(>3 cm)原发性肺癌患者的优选治疗。

研究设计与样本

  • 研究纳入2010年11月1日至2022年12月31日期间126例大(>3 cm)原发性肺癌患者,其中临床诊断61例(48.4%)、病理诊断65例(51.6%)。
  • 患者接受风险适应性立体定向放疗,分次方案中位5次,总剂量60 Gy(范围45-63 Gy)。
  • 采用逻辑回归模型进行倾向评分匹配,并进行1:1比例匹配及逆概率治疗加权以平衡基线特征差异。
  • 采用Cox比例风险模型进行单因素和多因素分析,以识别影响总生存和无进展生存的预后因素。

主要发现

  • 倾向评分匹配与逆概率治疗加权后,临床诊断与病理诊断患者在总生存、无进展生存、肿瘤失败及癌症特异性死亡方面未见差异。
  • 单因素和多因素分析确定Charlson合并症指数≥5为总生存和无进展生存的不良预后因素。
  • 病理诊断组1例(0.8%)在立体定向放疗后2个月发生5级肺炎。

临床怎么用

  • 作者结论认为风险适应性立体定向放疗可能是经过适当选择的、缺乏组织学确诊的大(>3 cm)原发性肺癌患者的优选治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Stereotactic body radiation therapy (SBRT) is a promising therapeutic approach for inoperable, small (≤3 cm) primary lung cancer. However, the efficacy and safety of risk-adapted SBRT for treating large (>3 cm) primary lung cancer remains inadequately characterized. PATIENTS AND METHODS: Patients with large (>3 cm) primary lung cancer, diagnosed either clinically or histologically, were recruited between November 1, 2010 and December 31, 2022. Risk-adapted SBRT was administered in fractions (median, 5) for a total dose of 60 Gy (range, 45-63 Gy). The primary endpoint was overall survival (OS), and secondary endpoints included progression-free survival (PFS), local failure (LF), regional failure (RF), distant metastasis (DM), cancer-specific mortality (CSM), and toxicity. Differences in baseline characteristics were balanced via propensity score matching (PSM) with the logistic regression model, as well as 1:1 ratio matching and inverse probability of treatment weighting (IPTW). The Cox proportional hazards model was used for univariate and multivariate analyses aimed at identifying prognostic factors influencing OS and PFS. RESULTS: The 126 enrolled patients included 61 cases (48.4 %) diagnosed clinically and 65 cases (51.6 %) diagnosed pathologically. Following PSM and IPTW, no differences were found between patients diagnosed clinically versus pathologically in OS, PFS, tumor failure, and CSM. Univariate and multivariate analyses identified a Charlson comorbidity index ≥5 as an adverse prognostic factor for OS and PFS. One patient (0.8 %) in the pathologically diagnosed group developed grade 5 pneumonitis 2 months after undergoing SBRT. CONCLUSIONS: Risk-adapted SBRT may be an optimal treatment for appropriately selected patients with a large (>3 cm) primary lung cancer lacking histologic confirmation.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Zeng HY, Li YJ, Ji CZ, et al. Risk-adapted stereotactic body radiation therapy for the treatment of large (>3 cm) primary lung cancer with or without histologic confirmation: A propensity score matched and weighted analysis. Radiother Oncol. 2025. PMID: 39933623. doi:10.1016/j.radonc.2025.110781

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。